Asa Henin represents private and public companies in a wide range of corporate and securities matters, including public offerings, private financings, Securities and Exchange Commission reporting and compliance, corporate governance matters, mergers and acquisitions, and employment and compensation arrangements. Asa regularly acts as outside corporate counsel to public and private life sciences companies. He also advises venture capital firms in connection with financings.

Download full bio 


  • Longboard Pharmaceuticals – $80 Million IPO 

  • Kronos Bio – $288 million IPO 

  • Turning Point Therapeutics - $192 Million IPO 

  • Allogene Therapeutics – $372.6 Million IPO 

  • Synthorx: $63 Million Series C Financing 

  • View all


  • University of San Diego School of Law
    JD, magna cum laude, magna cum laude, 2010

  • University of California, Santa Barbara
    BA, 2006

Admissions & Credentials



  • State Bar of California

Rankings & Accolades

    CALI Awards in Corporations and Securities Regulation, Recipient

Representative transactions include:

  • Allogene Therapeutics – $372.6 million IPO
  • Synthorx Therapeutics – $63 million Series C Financing
  • Arena Pharmaceuticals – $405.7 million Public Offering